Shareholding for the Period Ended December 31, 2017
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here10-01-2018
10-01-2018
Natco launches tenofovir alafenamide 25 mg for treating hepatitis B
Natco Pharma has launched a generic version of tenofovir alafenamide (TAF) 25mg used for the treatment of hepatitis B. Patients can now take one tablet daily for the treatment of chronic hepatitis B in adults.20-12-2017
Natco a safer bet in volatile pharma pack
US sales are being driven by niche complex products, domestic specialty range is also seeing traction19-12-2017
Press Release / Media Release
NATCO launches TAFNAT, Tenofovir Alafenamide tablets, for treatment of chronic hepatitis B, in INDIA18-12-2017
Natco Pharma to raise Rs 915 cr through QIP
The Committee of Directors of Natco Pharma Limited has approved a move to raise about Rs 915 crore through qualified institutional placement. The committee, which met on Friday, approved the...16-12-2017
Natco Pharma, a high durability stock, gains sharply on money raise
Natco Pharma is among the top stocks in terms of its durability score, but is seeing increasingly expensive valuation since sharp gains over the past one year. The company was among the top share price gainers today after news that it raised Rs. 915 crore via QIP. The company's committee of directors decided to allocate 1 crore shares at issue price of Rs 915 apiece. Natco has plans overall to raise Rs. 1,500 crore via equity, in order to invest into the complex generics space in the US over the long-term. The company's gTamiflu offering tends to have strong sales in the flu season in the US between November to March, and therefore analysts expect it to boost the sales for that quarter.14-12-2017